DelveInsight’s, “Acute Ischemic Stroke (AIS) – Pipeline Insight, 2022,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acute Ischemic Stroke (AIS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Acute Ischemic Stroke (AIS): Overview
Acute Ischemic Stroke (AIS) results from a sudden cessation of adequate amounts of blood reaching parts of the brain. Ischemic strokes can be divided according to territory affected or mechanism. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, the more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain. Symptoms depend on severity of the stroke and location in the brain. Some people do not experience any symptoms and others experience only one. Symptoms may include: Paralysis on one side of the body, Change in alertness, Changes in hearing or taste, Problems swallowing, Dizziness or loss of balance, and Problems with eyesight. Treatment consists of one or a combination of two basic approaches to restore proper blood flow: 1) an injection of a clot-busting drug and 2) mechanical thrombectomy, a minimally-invasive procedure that physically removes clot from blocked arteries.
"Acute Ischemic Stroke (AIS) - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Ischemic Stroke (AIS) pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke (AIS) treatment guidelines. The assessment part of the report embraces, in depth Acute Ischemic Stroke (AIS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke (AIS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Acute Ischemic Stroke (AIS) R&D. The therapies under development are focused on novel approaches to treat/improve Acute Ischemic Stroke (AIS).
This segment of the Acute Ischemic Stroke (AIS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Ischemic Stroke (AIS) Emerging Drugs
Nerinetide: NoNO
Nerinetide (formerly NA 1) is being developed by Arbor Vita Corporation (USA) and NoNO Inc. Nerinetide is an eicosapeptide that inhibits post-synaptic density protein 95 (PSD-95) signaling. It is believed to act as a neuroprotectant that promotes cell survival and disrupts toxic cell signals following damage to neurons. The drug is in Phase III stage of development for the treatment of patients with Acute Ischemic Stroke (AIS).
DM199: DiaMedica therapeutics
DM199 is a recombinant (synthetic) form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) that plays an important role in the regulation of diverse physiological processes including blood flow, inflammation, fibrosis, oxidative stress and neurogenesis via a molecular mechanism that increases production of nitric oxide and prostaglandin. KLK1 deficiency may play a role in multiple vascular and fibrotic diseases such as chronic kidney disease, retinopathy, stroke, vascular dementia, and resistant hypertension where current treatment options are limited or ineffective. DiaMedica is the first company to have developed a recombinant form of the KLK1 protein. The KLK1 protein, produced from porcine pancreas and human urine, has been used to treat patients in Japan, China and South Korea for decades. DM199 is currently being studied in patients with acute ischemic stroke and chronic kidney disease.
Pro-UK: Tasly Pharmaceutical
Recombinant human (rh) Pro-UK, is a novel type of thrombolytic, which preferentially activates plasminogen on the fibrin surface and induces fibrin-selective clot lysis. The drug is in Phase III clinical trials in Acute Ischemic Stroke (AIS).
Further product details are provided in the report……..
This segment of the report provides insights about the different Acute Ischemic Stroke (AIS) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 22+ key companies which are developing the therapies for Acute Ischemic Stroke (AIS). The companies which have their Acute Ischemic Stroke (AIS) drug candidates in the most advanced stage, i.e. Phase III include, NoNO.
DelveInsight’s report covers around 22+ products under different phases of clinical development like
Acute Ischemic Stroke (AIS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Ischemic Stroke (AIS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Ischemic Stroke (AIS) drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Acute Ischemic Stroke (AIS): Overview
Pipeline Therapeutics
Therapeutic Assessment
Acute Ischemic Stroke (AIS) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute Ischemic Stroke (AIS) Collaboration Deals
Late Stage Products (Phase III)
Nerinetide: NoNO
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Elezanumab: AbbVie
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
JTR-161: Teijin Pharma Limited
Drug profiles in the detailed report…..
Inactive Products
Acute Ischemic Stroke (AIS) Key Companies
Acute Ischemic Stroke (AIS) Key Products
Acute Ischemic Stroke (AIS)- Unmet Needs
Acute Ischemic Stroke (AIS)- Market Drivers and Barriers
Acute Ischemic Stroke (AIS)- Future Perspectives and Conclusion
Acute Ischemic Stroke (AIS) Analyst Views
Acute Ischemic Stroke (AIS) Key Companies
Appendix
List of Table
Table 1: Total Products for Acute Ischemic Stroke (AIS)
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Acute Ischemic Stroke (AIS)
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• AbbVie
• Biogen
• NoNO Inc.
• Acticor Biotech
• DiaMedica Therapeutics
• Lumosa therapeutics
• Tasly Pharmaceutical
• Pharmazz, Inc.
• Healios K.K.
• Nanjing Yoko Biomedical
• Jeil Pharmaceutical
• Bristol-Myers Squibb/Janssen Pharmaceuticals
• Pharming Technologies B.V.
• Shin Poong Pharmaceutical
• Clinuvel Pharmaceuticals
• Teijin Pharma Limited
• Daiichi Sankyo, Inc.
• aptaTargets S.L.
• Meridigen Biotech
• Suzhou Yabao Pharmaceutical
• Prolong Pharmaceuticals
• Ever Supreme Bio Technology
• NuvOx LLC
• Aeromics
